MODD stock forecast, quote, news & analysis
Modular Medical Inc is a development stage medical device company which focuses on the design, development, marketing and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace... Show more
Why Modular Medical (MODD) Stock Is Down -49% in the Last 30 Days
Key Takeaways
- MODD shares fell roughly 49% over the past 30 days, retreating from about $3.76 to near $1.92 as a sharp August rally reversed.
- The decline follows a speculative run-up tied to commercialization milestones for the company's Pivot tubeless insulin patch pump.
- Over the most recent quarter, the stock declined approximately 59% from about $4.68, underscoring sustained volatility.
- Modular Medical is an early-commercial micro-cap with a market capitalization near $15 million, making the shares prone to outsized swings.
- Upcoming catalysts include the October 2026 commercial launch across five U.S. markets and progress toward European CE Mark approval.
Modular Medical (MODD) Company Overview and Market Position
Modular Medical, Inc. is a San Diego-based medical device company focused on insulin delivery technology. Its flagship product, the Pivot tubeless insulin patch pump, is designed as a simpler, more affordable alternative to traditional insulin pumps for adults with type 1 or type 2 diabetes. The device features a removable two-part design with a 3 mL reservoir, a disposable battery, smartphone connectivity for bolus delivery and monitoring, and a quick bolus button that operates without a separate controller.
The company targets the large population of insulin-dependent adults who remain on multiple daily injections, a segment it describes as "almost-pumpers." Modular Medical was founded by Paul DiPerna, who previously founded Tandem Diabetes Care and designed its t:slim pump. Pivot received FDA 510(k) clearance in April 2026, positioning the company to compete alongside established insulin pump makers such as Insulet and Medtronic.
Modular Medical (MODD) Stock Price Performance: Last 30 Days vs. Quarter
MODD has been highly volatile across both time frames. Over the last 30 days, the stock fell approximately 49%, declining from a closing price of $3.76 on August 31 to near $1.92 in late September. The move erased most of a sharp rally that had briefly carried shares above $4.00 on an intraday basis in late August.
The broader quarterly trend tells a similar story of amplified swings. From a closing price near $4.68 at the start of July, MODD declined roughly 59% to its current level. Within that period, the stock dropped into the low-$2 range by late July, rebounded to roughly $3.79 by late August, and then reversed again through September. The shares have traded near a 52-week low of $1.72, reflecting both the early stage of commercialization and persistent selling pressure.
What Drove MODD Stock Price in the Last 30 Days
The sharp pullback over the past 30 days came after a rapid August advance driven by commercialization news. In early August, Modular Medical announced plans to begin the first phase of its Pivot launch in October across five U.S. markets—Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia—with commercialization partner Inizio. The company also secured a contract with a national U.S. pharmacy benefit manager, and on September 3 the FDA cleared software enhancements to the Pivot system, including customizable bolus dosing and user-interface upgrades.
Those catalysts fueled a brief surge, but the gains were not sustained. Shares gave back most of the rally in September as investors weighed the company's pre-revenue status ahead of the October launch. Contributing factors included profit-taking after the run-up, ongoing at-the-market equity sales that dilute existing shareholders, and recurring concerns about liquidity and a going-concern warning. The company reported a net loss of approximately $6.5 million for its fiscal first quarter, and its micro-cap valuation leaves the stock especially sensitive to changes in sentiment.
What Drove MODD Stock Performance Over the Last Quarter
The most recent quarter marked Modular Medical's transition from a development-stage company toward commercial operations. In late June, the company announced that its first patients had begun using the Pivot pump in real-world settings. This was followed by the five-market launch announcement in August, the pharmacy benefit manager contract, and the September FDA clearance of software enhancements.
Despite these operational milestones, the stock declined over the full quarter. Investors continue to weigh meaningful progress against the realities of an early-commercial company: limited near-term revenue, ongoing capital raises, and a competitive insulin pump market dominated by larger, better-funded rivals. The net result was a highly volatile three-month stretch in which positive headlines produced short-lived rallies that ultimately faded.
Trending AI Robots
For traders seeking a systematic way to monitor moves like those in MODD, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron operates hundreds of AI trading bots that track thousands of tickers, but only the top-performing and most relevant bots are featured in this section. Each bot differs in strategy, timeframe, and performance metrics, giving users a range of approaches to explore rather than a single one-size-fits-all signal. Reviewing the page can help investors understand how automated systems are positioned across the market and identify strategies that may align with their own research process.
MODD Stock Forecast Drivers: What Investors Should Watch Next
The clearest near-term catalyst is the October 2026 commercial launch of the Pivot pump across the five selected U.S. markets. Early adoption metrics, initial revenue contributions, and feedback from patients and providers will be closely watched as signs of whether the launch is gaining traction. Investors will also monitor progress toward CE Mark approval, targeted for the fourth quarter of 2026 or first quarter of 2027, which would open European and other international markets.
Beyond the launch, key considerations include the pace of additional software enhancements and automated insulin delivery features, the company's ability to manage cash and any future capital raises, and competition from larger insulin pump and diabetes technology incumbents. As with any early-commercial medical device company, execution risk and financing conditions remain central factors that could influence the stock's direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MODD in downward trend: 10-day moving average moved below 50-day moving average on September 16, 2026
The 10-day moving average for MODD crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 20 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MODD as a result. In 91 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for MODD turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
MODD moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MODD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MODD entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MODD's RSI Indicator exited the oversold zone, 39 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 60 cases where MODD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where MODD advanced for three days, in 180 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
MODD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.518) is normal, around the industry mean (10.853). P/E Ratio (0.000) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (39.828).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. MODD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MODD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices